Trial · NCT03182244
Results by group148
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 148
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Overall Survival (OS) | Gilteritinib | 10.3 | 95% Confidence Interval 8.8 to 12.7 | months | |
| Overall Survival (OS) | Salvage Chemotherapy | 5.4 | 95% Confidence Interval 4.1 to 8.1 | months | |
| Event-Free Survival (EFS) | Gilteritinib | 2.1 | 95% Confidence Interval 0.1 to 3.2 | months | |
| Event-Free Survival (EFS) | Salvage Chemotherapy | 0.6 | 95% Confidence Interval 0.2 to 1.2 | months | |
| Complete Remission (CR) Rate | Gilteritinib | 20.4 | 95% Confidence Interval 14.0 to 28.2 | Percentage of participants | |
| Complete Remission (CR) Rate | Salvage Chemotherapy | 11.5 | 95% Confidence Interval 6.7 to 18.0 | Percentage of participants | |
| Duration of CR | Gilteritinib | 24.0 | 95% Confidence Interval 4.6 to NA | months | |
| Duration of CR | Salvage Chemotherapy | NA | 95% Confidence Interval 1.0 to NA | months | |
| Duration of Composite Complete Remission (CRc) | Gilteritinib | 4.1 | 95% Confidence Interval 2.8 to 5.6 | months | |
| Duration of Composite Complete Remission (CRc) | Salvage Chemotherapy | NA | 95% Confidence Interval NA to NA | months | |
| Duration of CR/Complete Remission With Partial Hematologic Recovery (CRh) | Gilteritinib | 5.6 | 95% Confidence Interval 2.8 to 24.0 | months | |
| Duration of CR/Complete Remission With Partial Hematologic Recovery (CRh) | Salvage Chemotherapy | NA | 95% Confidence Interval NA to NA | months | |
| Duration Of Response (DOR) | Gilteritinib | 3.7 | 95% Confidence Interval 2.5 to 4.7 | months | |
| Duration Of Response (DOR) | Salvage Chemotherapy | NA | 95% Confidence Interval 1.2 to NA | months | |
| CR/CRh Rate | Gilteritinib | 32.1 | 95% Confidence Interval 24.4 to 40.6 | Percentage of participants | |
| CR/CRh Rate | Salvage Chemotherapy | 14.4 | 95% Confidence Interval 9.0 to 21.3 | Percentage of participants | |
| Best Response Rate | Gilteritinib | CR | 20.4 | Percentage of participants | |
| Best Response Rate | Salvage Chemotherapy | CR | 11.5 | Percentage of participants | |
| Best Response Rate | Gilteritinib | CRp | 13.1 | Percentage of participants | |
| Best Response Rate | Salvage Chemotherapy | CRp | 0.7 | Percentage of participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03182244/results